ICD-10-CM Billable Code

M36.0

Dermato(poly)myositis in neoplastic disease

Clinical Classification Guidelines

Code First

  • underlying neoplasm (C00-D49)

Medical Intelligence & Overview

Dermatomyositis is a rare inflammatory disease that causes muscle weakness and skin rash. When it occurs alongside neoplastic diseases, such as cancer, it is classified under ICD-10 code M36.0. This association can complicate diagnosis and management, as the symptoms may mimic other conditions, and treatment often requires a multidisciplinary approach. Recognizing dermatomyositis in patients with neoplastic disease is essential for effective care and may also serve as a marker for underlying malignancy.

Causes & Symptoms

Clinical Causes: Autoimmune response where the body's immune system attacks skin and muscle tissues. Underlying neoplastic processes, particularly certain cancers like ovarian, lung, pancreatic, stomach, and colorectal cancers. Possible genetic predispositions and environmental factors contributing to immune dysregulation. Paraneoplastic phenomenon, where the immune response to tumor cells triggers inflammatory muscle and skin conditions.

Key Symptoms: Muscle weakness, especially in the proximal muscles such as hips, shoulders, and neck. Skin abnormalities including a distinctive reddish or purple rash often found on the face, knuckles, elbows, knees, and chest. Difficulty swallowing or speaking due to muscle involvement. Fatigue and general discomfort. Swelling and tenderness in affected muscles. Gottron's papules—raised, scaly bumps over joint areas, especially knuckles. Heliotrope rash—violaceous rash around the eyelids.

Diagnostic & Treatment

Diagnosis Path: Medical history review focusing on symptom onset and associated malignancies. Physical examination emphasizing skin findings and muscle strength assessment. Blood tests including muscle enzymes like creatine kinase (CK), aldolase, and inflammatory markers such as ESR and CRP. Autoantibody testing to identify specific myositis-associated antibodies. Electromyography (EMG) to assess electrical activity in muscles. Muscle and skin biopsies for histopathological examination. Imaging studies such as MRI to detect muscle inflammation. Cancer screening and imaging, like CT scans, mammography, or endoscopy, to identify underlying neoplasms.

Treatment Protocols: Immunosuppressive therapies, including corticosteroids to reduce inflammation. Other immunomodulators such as methotrexate, azathioprine, or mycophenolate mofetil. Intravenous immunoglobulin (IVIG) in resistant cases. Treating the underlying neoplasm with appropriate cancer therapies like surgery, chemotherapy, or radiation. Physical therapy to maintain muscle strength and function. Symptomatic treatments for skin manifestations, including topical corticosteroids. Regular monitoring for treatment efficacy and side effects. Supportive care addressing swallowing difficulties or other complications.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M36.0 a billable ICD-10 code?
Yes, M36.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M36.0?
Clinical documentation must specify the nature of Dermato(poly)myositis in neoplastic disease and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Related Diagnosis Codes

Clinical Meta Tags

neoplastic disease